CytoSorbents to Exhibit at the 43rd Annual Meeting of the German Society for Thoracic, Heart and Vascular Surgery

CytoSorbents to Exhibit at the 43rd Annual Meeting of the German Society for 
Thoracic, Heart and Vascular Surgery 
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 02/05/14 --  CytoSorbents
Corporation (OTCQB: CTSO), a critical care immunotherapy company,
announced that it will exhibit at the 43rd Annual Meeting of the
German Society for Thoracic, Heart and Vascular Surgery in Freiburg,
Germany from February 9-12, 2014. The conference is in cooperation
with the Austrian and Swiss Societies for Thoracic and Cardiovascular
Surgery. 
Cardiothoracic surgery accounts for approximately 1.5 million
open-heart surgeries performed worldwide each year, for procedures
such as coronary artery bypass graft surgery (for blocked coronary
arteries), valve replacement surgery, left ventricular assist device
implantation (for end-stage heart failure), and heart and/or lung
transplant. Former President Bill Clinton and comedian David
Letterman are amongst those notable for having open-heart surgery for
heart disease.  
In order to operate on the heart, the heart is typically stopped,
with blood shunted away from the heart and lungs, to a
cardiopulmonary bypass (CPB) machine, also known as a heart-lung
machine, outside of the body. The machine oxygenates the blood and
then pumps the blood at high pressure back to the rest of the body.
Patients can develop serious post-operative complications such as
kidney and lung failure due to the production of inflammatory
cytokines, and the release of free hemoglobin by damaged red blood
cells.  
CytoSorb(R) is the only specifically approved extracorporeal cytokine
filter in the European Union that can be easily installed into a
bypass circuit of the CPB machine without the need for an additional
blood pump. CytoSorb(R) directly removes a broad range of cytokines
and free hemoglobin from blood, and is a superior drop-in replacement
for leukoreduction filters, an existing commercial product that
tries, but cannot remove cytokines or free hemoglobin directly.
CytoSorb(R) is being used today in a growing number of major heart
centers throughout Germany and Austria, in both regular clinical
usage and in investigator initiated studies. It is used both
intra-operatively, as well as during the recovery phase in patients
that develop a post-operative systemic inflammatory response syndrome
(SIRS). Cardiac surgery represents a total addressable market for
CytoSorb(R) of $0.5 - 1.0 billion in Europe and the U.S. alone.  
Dr. Christian Steiner, MD, Vice President of Sales and Marketing of
CytoSorbents, stated, "This conference is the most important
cardiothoracic surgery meeting in the German speaking community. It
attracts cardiac surgeons and heart-lung machine perfusionists from
across the region. In order to accelerate sales of CytoSorb(R) for
this segment, we recently hired a very experienced cardiac surgery
sales representative with extensive key opinion leader contacts in
our direct markets. Her focus will significantly add to the momentum
generated by the rest of the sales team in this application. We
benefit from encouraging early clinical data generated by our
collaborators, a unique competitive position, and a strong value
proposition. We see cardiac surgery as a very robust additional
market to the critical care applications that we continue to pursue
aggressively." 
About CytoSorbents Corporation 
 CytoSorbents is a critical care
focused immunotherapy company using blood purification to modulate
inflammation -- with the goal of preventing or treating multiple
organ failure in life-threatening illnesses. Organ failure is the
cause of nearly half of all deaths in the intensive care unit, with
little to improve clinical outcome. CytoSorb(R), the Company's
flagship product, is approved in the European Union as a safe and
effective extracorporeal cytokine filter, designed to reduce the
"cytokine storm" that could otherwise cause massive inflammation,
organ failure and death in common critical illnesses such as sepsis,
burn injury, trauma, lung injury, and pancreatitis. These are
conditions where the mortality is extremely high, yet no effective
treatments exist. In addition, CytoSorb(R) can be used in other
inflammatory conditions such as cardiac surgery and autoimmune
disease flares. CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. CytoSorbents has numerous products under
development based upon this unique blood purification technology,
protected by 32 issued US patents and multiple applications pending,
including HemoDefend(TM), ContrastSorb, DrugSorb, and others.
Additional information is available for download on the Company's
website: http://www.cytosorbents.com/ 
Forward-Looking Statements
 This press release includes
forward-looking statements intended to qualify for the safe harbor
from liability established by the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press release
are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ
materially from those anticipated. These statements are based on
management's current expectations and assumptions and are naturally
subject to uncertainty and changes in circumstances. We caution you
not to place undue reliance upon any such forward-looking statements.
Actual results may differ materially from those expressed or implied
by the statements herein. Risk factors are detailed in the Company's
Form 10-K filed with the SEC on April 3, 2013, which is available at
http://www.sec.gov. 
Company Contact: 
CytoSorbents Corporation
Dr. Phillip Chan
Chief Executive Officer 
(732) 329-8885 ext. *823
pchan@cytosorbents.com 
Investor Contact: 
CytoSorbents Corporation
Amy Vogel
(732) 329-8885 ext. *777
avogel@cytosorbents.com 
 
 
Press spacebar to pause and continue. Press esc to stop.